At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 10 enrolled
Drug / intervention
Tacrolimus +1 moredrug
Likely dose
Tacrolimus 0.04 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Use of Sublingual Tacrolimus in Adult Blood and Marrow Transplant Patients: a Pilot Study
In Brief
A Phase 4 clinical trial evaluating Tacrolimus for Immunosuppression and 2 related conditions. Completed, enrolled 10 participants across 1 site.
Detailed Summary
Researchers are trying to learn more about using sublingual (absorption under the tongue) tacrolimus in blood and marrow transplant patients.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
2020202120222023202420252026
Enrollment StartJun 2019
First PostedAug 2019
Primary CompletionOct 2019
TodayJul 2026
First PostedAug 1, 2019
Enrollment StartJun 17, 2019
Primary CompletionOct 8, 2019
TodayJul 2, 2026
Enrollment to primary: 4 monthsPosted 6.9 years ago
Interventions
Tacrolimusdrug
Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), initially administered sublingually for four consecutive doses.
Tacrolimusdrug
Recommended starting dose will be in accordance with the established protocol (0.04 mg/kg/dose of ideal body weight), oral administration after sublingual four consecutive doses